ACCESS Newswire
24 Nov 2022, 14:01 GMT+10
STOCKHOLM, SE / ACCESSWIRE / November 24, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0) STOCKHOLM, 24 November 2022 - Promore Pharma AB (publ) publishes its interim report for the third quarter 2022 on 29 November 2022.
The day after, the 30 November at 11:00 CET, the company will host a webcast telephone conference with President and CEO Jonas Ekblom, whith an update for the quarter and upcoming activities. After the presentation there will be a Q&A session. The conference call will be held in Swedish and can be accessed via computer, tablet, or telephone.
The number of attendees is limited, please register for the conference in advance on the following link:
https://attendee.gotowebinar.com/register/6302336206518108940
The conference call will be recorded and made available on the company´s website after the call, and on Västra Hamnen Corporate Finance Youtube channel.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: [email protected]
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: [email protected]
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: [email protected]
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is undergoing a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
Attachments
Invitation to Conference Call regarding Promore Pharma's Interim Report for the Third Quarter 2022
SOURCE: Promore Pharma
Get a daily dose of North Carolina Daily news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to North Carolina Daily.
More InformationBATTLE CREEK, Michigan: In a major consolidation of iconic food brands, WK Kellogg has agreed to be acquired by the owner of Ferrero...
CONCORD, New Hampshire: A federal judge in New Hampshire issued a crucial ruling on July 10 against President Donald Trump's executive...
WASHINGTON, D.C.: Filmmaker Peter Jackson's lifelong fascination with the extinct giant New Zealand flightless bird called the moa...
DUBAI, U.A.E.: A cargo ship flagged under Liberia, known as the Eternity C, sank in the Red Sea following an attack executed by Yemen's...
NEW DELHI, India: India has submitted a revised proposal to the World Trade Organization (WTO) in Geneva to implement retaliatory tariffs...
WASHINGTON, D.C.: The Trump administration has started sending some weapons to Ukraine again, just a week after the Pentagon told officials...